InPen™ Smart Insulin Pen data shows the system's unique reminders improve treatment outcomes for those using multiple daily injections

Results show that the use of InPen resulted in an increase in Time in Range among those in the studies

DUBLIN – June 23, 2023 –Medtronic plc(NYSE:MDT), the global leader in medical technology, presented an oral presentation and a late-breaking poster on its InPen™ Smart Insulin Pen (SIP). These latest results were presented this weekend at the 83rd American Diabetes Association (ADA) Scientific Sessions in San Diego, CA.

The oral presentation, which was presented at ADA on Friday, June 23, reported on the impact of meal-dosing behavior (missed and late) on glycemic control in adult and pediatric InPen users with type 1 or type 2 diabetes (n=5,153) and found that more frequent on-time dosing correlated with improved Time in Range.

	<3 doses/day (N=1,909)	>3 doses/day (N=3,244)	
	--	Missed Dose Rate ≥20% (N=2,282)	Missed Dose Rate <20% (N=962)
Number of Detected Meals	3.9	5.0*	4.6*
Correction Dose Frequency[a]	17%	22%*	16%
Dose Timing			
On-Time	45%	51%*	75%*
Late	9%	14%*	13%*
Missed	47%	35%*	12%*
Glycemic Outcomes			
GMI	7.9%	7.6%*	7.0%*
TIR	52%	56%*	70%*
TBR	1.8%	2.1%	2.9%*
TAR	46%	42%*	27%*

TBR = Time Below Range; TIR = Time In Range; TAR = Time Above Range; GMI = Glucose Management Indicator.

[a]Percentage of detected doses that were correction-only doses.

*ANOVA to test difference between groups and Tukey's Test for post-hoc analysis. Significance level set at 0.05.

The late-breaking poster presentation, which will be presented on Saturday, June 24, evaluated the impact of correction dose timing (n=857), leveraging the system's unique ability to track active insulin, among adult and pediatric InPen users with type 1 or type 2 diabetes. The study found that those that delivered at least one correction dose per day within 3 hours of a previous dose, associated with more doses per day, achieved higher Time in Range, without an increase in Time Below Range, when compared to those that gave a correction dose

more than three hours after the previous dose.

“This data adds to the growing body of evidence that the use of intelligent dosing systems that go beyond just providing a number and in addition provide an action not only provide clinical benefits, as those demonstrated in these studies, but also help to simplify diabetes management by reducing the number of decisions individuals need to make on a daily basis,” said Robert Vigersky, Chief Medical Officer, Medtronic Diabetes. “We are pleased to be able to bring the widest breadth of solutions and meet individuals where they are in their diabetes journey regardless of how they prefer to dose their insulin.”

The InPen™ is a reusable smart insulin pen that uses Bluetooth® technology to send dose information to a mobile app. Offering dose calculations and tracking, InPen helps take some of the mental math out of diabetes management.

Medtronic is committed to simplifying and improving diabetes management through the advancement of smart algorithms with reduced patient input. These strong clinical and real-world data findings support the company’s mission to continuously deliver new technology that helps people achieve better glucose control and spend less time managing highs and lows.

About Medtronic Diabetes (www.medtronicdiabetes.com)
Medtronic Diabetes is on a mission to alleviate the burden of diabetes by empowering individuals to live life on their terms, with the most advanced diabetes technology and always-on support when and how they need it. We’ve pioneered first-of-its-kind innovations for over 40 years and are committed to designing the future of diabetes management through next-generation sensors (CGM), intelligent dosing systems, and the power of data science and AI while always putting the customer experience at the forefront.

About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Dublin, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 90,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic (NYSE:MDT), visit www.Medtronic.com and follow @Medtronic on Twitter and LinkedIn.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

Additional assets available online: Photos (

https://news.minimed.com/2023-06-23-InPen-TM-Smart-Insulin-Pen-data-shows-the-systems-unique-reminders-improve-treatment-outcomes-for-those-using-multiple-daily-injections